Developing a synagis clinic for respiratory syncytial virus prophylaxis.
Respiratory Syncytial Virus (RSV) can be devastating to premature infants and children with chronic lung disease. Palivizumab (Synagis) is a monoclonal antibody that is administered monthly by injection to prevent RSV infection in infants at high risk. This article describes a nurse-run ambulatory clinic to provide RSV prophylaxis. Coordination with other agencies, including community neonatal intensive care units, was essential to the clinic's success. For each of its first 2 years of operation, 24 infants and their families attended the clinic once each month for 5 months throughout the RSV season. Outcomes for this patient population were compared to outcomes reported in the literature, and include reduced RSV-related hospitalizations and reduced days of hospitalization.